Skip to main content
Viatris Inc logo

Viatris Inc — Investor Relations & Filings

Ticker · VTRS ISIN · US92556V1061 LEI · 254900ZZTSW7NL773X71 US Manufacturing
Filings indexed 489 across all filing types
Latest filing 2025-12-05 Regulatory Filings
Country US United States of America
Listing US VTRS

About Viatris Inc

https://www.viatris.com/en

Viatris Inc. is a global healthcare company focused on empowering people to live healthier at every stage of life. The company operates by bridging the divide between generic and branded medicines, combining aspects of both to enhance patient access worldwide. Its portfolio comprises a wide range of high-quality medicines, including oral solid doses, injectables, complex dosage forms, and active pharmaceutical ingredients (APIs). These products cover numerous therapeutic areas, addressing both noncommunicable and infectious diseases. Viatris's offerings treat many of the World Health Organization's leading causes of death. The company continues to expand its capabilities, including recent acquisitions to strengthen its presence in the central nervous system (CNS) therapeutic area.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings
2025-12-05 English
8-K/A
Regulatory Filings
2025-12-05 English
Europaische Studie zeigt sinkende Preise, steigende Kosten und Engpasse - Ergebnisse einer unabhangigen Studie, die wahrend der World AMR Awareness Week von Viatris und Medicines for Europe vorgestell
Environmental & Social Information Classification · 100% confidence The document is a press release announcing the findings of an independent study regarding antibiotic shortages and pricing, sponsored by Viatris and Medicines for Europe. It provides a summary of the study's key findings and includes quotes from company executives. It does not constitute a formal financial report, audit, or regulatory filing, but rather a corporate news announcement. As it is a general regulatory announcement that does not fit into more specific categories like Earnings Release or Investor Presentation, it is classified as a Regulatory Filing (RNS).
2025-11-20 German
European study shows falling prices, rising costs and shortages - findings from independent study presented during World AMR Awareness Week by Viatris and Medicines for Europe
Regulatory Filings Classification · 100% confidence The document is a press release issued by Viatris Inc. regarding the findings of an independent study on antibiotic shortages and pricing. It is not a formal financial report, audit, or regulatory filing, but rather a corporate communication/press release intended for public dissemination. According to the classification guidelines, general corporate news and press releases that do not fit into specific categories like 'Earnings Release' or 'Annual Report' are best classified as 'Regulatory Filings' (RNS) as the fallback category for miscellaneous corporate announcements.
2025-11-19 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-11-10 English
10-Q
Interim / Quarterly Report Q3 2025
2025-11-06 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.